A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Status:
Completed
Trial end date:
2017-12-23
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, single-dose study to assess the PK of a single oral dose of 3 mg
CC-122 in subjects with mild, moderate, and severe renal impairment as compared to sex, age
(± 15 years), and weight (± 20%) matched control subjects with normal renal function.